NanogroupS.A.

Activities of holding companies

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2016-12-02
Share capital
42 628 988,00 PLN
Activity description

NanoGroup SA is building a biotechnology group and developing projects in nanotechnology for medicine. Its projects include NanOX Recovery Box, NanOX 4 Kidney, AUX-001, and a pipeline with dextran conjugates and aptamers. The company also lists development milestones such as non-GLP studies, GMP batch production, and CE certification.

Registered address
ul. Rakowiecka 36, 02-532 Warszawa, Poland
Website
nanogroup.euWebsite active
Phone
Social media
Electronic delivery address
AE:PL-22876-83677-EBSWU-17

Financials

The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Stock quotes

PLN 2.39
+0.02 (+1.06%)
2.362.382.402.422.3910:0012:0014:0016:00
Open
PLN 2.40
High
PLN 2.42
Low
PLN 2.35
Volume
19.63K
Avg. vol.
24.6K
Market cap
PLN 101.67M
P/E ratio
–
EPS
-PLN 0.27
Shares outstanding
42.63M
52-week
PLN 2.26 – 2.50
Dividend yield
–
Dividend
–
Ex dividend date
–
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q2 2026USD -33.77kUSD -1.19mUSD -1.16m
Q1 2026USD 33.77kUSD -613.99kUSD -604.27k
Q4 2025USD -1.76kUSD -972.12kUSD -963.84k
Q3 2025USD 1.76kUSD -331.74kUSD -284.53k

Results for Q3 2026:Oct 29, 2026

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2024.

Results vs industry

Revenue
This companyUSD 843.10kMedianUSD 45.51kAverageUSD 5.08m
Net profit
This companyUSD -478.08kMedianUSD 39.70AverageUSD 870.23k
Operating costs
This companyUSD 870.30kMedianUSD 11.21kAverageUSD 3.50m
Assets
This companyUSD 10.54mMedianUSD 876.56kAverageUSD 23.59m

Bank accounts

Registered as a VAT taxpayer on 2017-07-20. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Public aid

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$4
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$1,282
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$1

Tenders

No recorded participation in tenders.

Authorized Representatives

Tomasz Adam Ciach – Management Board Member
Przemysław Daniel Mazurek – President of the Management Board
Zbigniew Jerzy Posłajko – Attorney-in-fact (sole)
Piotr Paweł Mierzejewski – Vice President of the Management Board

Manner of representation

The following persons are authorized to make declarations of will on behalf of the company: in the case of a one-person management board, the President of the Management Board; in the case of a multi-member management board, two members of the management board or a member of the management board jointly with a commercial proxy.

Supervisory board

Jerzy Krzysztof Garlicki – Supervisory Board Member
Łukasz Ireneusz Gołębiewski – Supervisory Board Member
Tomasz Hubert Zastawny – Supervisory Board Member
Jakub Tatak – Supervisory Board Member
Rafał Płókarz – Supervisory Board Member

Beneficial owners

No beneficial owners recorded for the company Nanogroup.

Subsidiaries

NameStake
Doto Medicalsp. z o.o.
100%

Capital group

NameOwnership
Startventure@Poland Sp. z o.o
6.15%
Grupa Kapitałowa NanoGroup SA
7.17%
41%

Competitors

Name
Embud 2S.K.A.
Cemat Real EstateS.A.
BBI DevelopmentS.A.
Duda HoldingS.A.
5TH Avenue HoldingS.A.
Amestsp. z o.o.
EurofinanceS.A.
Invest-Motsp. z o.o.
ABRE Holdingsp. z o.o.
EQUOS.A.

Change history

DateEvent
2026-03-31Share capital change
2025-10-14Share capital change
2025-04-09Share capital change
2024-12-10Share capital change
2024-10-10Share capital change

FAQ

Last updated: 2026-10-07